Consensus Arcus Biosciences, Inc.

Stocks

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - NYSE 21:00:02 21/10/2026 BST			5-day change	1st Jan Change
19.10 ^USD	-19.58%		-15.15%	-19.85%

10-21	Wedbush Adjusts Price Target on Arcus Biosciences to $49 From $43, Keeps Outperform Rating	MT
10-20	Arcus Biosciences, Inc. - Special Call

Evolution of the Average Target: Arcus Biosciences, Inc.

Evolution of the Target Price: Arcus Biosciences, Inc.

Changes in Analyst Recommendations: Arcus Biosciences, Inc.

63663510f479.y_o-F1h31LPPSSuznckcQRI9BVyttzlzanOQHqo-FF0.oZhZYAkg7MKJA1-D5JpRKmNUaGvHjgogDxfaXeVJXSuBilQ6OQO54ogvGw~5635ca61d07fbf40b24c5991cf70dcef

Analysts' recommendations: Arcus Biosciences, Inc.

10-21	Wedbush Adjusts Price Target on Arcus Biosciences to $49 From $43, Keeps Outperform Rating	MT
10-16	William Blair Initiates Arcus Biosciences at Outperform	MT
10-14	JPMorgan Initiates Coverage on Arcus Biosciences With Overweight Rating, $41 Price Target	MT
09-16	TD Cowen Initiates Arcus Biosciences at Buy	MT
08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT
08-06	Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating	MT
08-03	BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25	MT
04-21	Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says	MT
04-02	Wedbush Raises Price Target on Arcus Biosciences to $41 From $37, Keeps Outperform Rating, Adds Stock to Best Ideas List	MT
02-12	Wells Fargo Downgrades Arcus Biosciences to Equal Weight From Overweight, Adjusts PT to $23 From $30	MT
01-08	Morgan Stanley Downgrades Arcus Biosciences to Equal Weight From Overweight, Cuts Price Target to $20 From $23	MT
12-12	Wedbush Adjusts Arcus Biosciences Price Target to $37 From $35, Maintains Outperform Rating	MT
12-12	Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating	MT
11-03	Mizuho Raises Price Target on Arcus Biosciences to $47 From $45, Keeps Outperform Rating	MT
29/10/25	Wedbush Raises Price Target on Arcus Biosciences to $35 From $33, Keeps Outperform Rating	MT
14/10/25	Arcus Biosciences, Inc. Announces First Overall Survival Results from Arm A1 of the Phase 2 EDGE-Gastric Study	CI
07/10/25	Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating	MT
18/08/25	Mizuho Raises Price Target on Arcus Biosciences to $45 From $42, Keeps Outperform Rating	MT
07/08/25	Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating	MT
06/08/25	Arcus Biosciences Q2 revenue beats analyst expectations	RE
09/05/25	Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating	MT
26/02/25	HC Wainwright Upgrades Arcus Biosciences to Buy From Neutral, Adjusts Price Target to $24 From $18	MT
18/02/25	Wedbush Cuts Arcus Biosciences' Price Target to $33 From $36, Keeps Outperform Rating	MT
21/10/24	HC Wainwright Initiates Coverage on Arcus Biosciences With Neutral Rating, $20 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARCUS BIOSCIENCES, INC.					+71.98%
	WUXI APPTEC CO., LTD.					+29.95%
	LONZA GROUP AG					+11.46%
	ARGENX SE					+29.38%
	IQVIA HOLDINGS INC.					+12.36%
	BEONE MEDICINES AG					+13.51%
	REVOLUTION MEDICINES, INC.					+31.18%
	CELLTRION, INC.					+35.68%
	WUXI BIOLOGICS (CAYMAN) INC.					+20.18%
	GENMAB A/S					+6.68%
	Average					+26.24%
	Weighted average by Cap.					+22.45%